Two SMA Drugs Move to Routine NHS Funding
NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy, ending time-limited managed access schemes in place since 2019. Medscape News UK
Original Source
Read the full article at Medscape →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.